Current Report Filing (8-k)
June 21 2022 - 07:14AM
Edgar (US Regulatory)
false000089394900008939492022-06-212022-06-21
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
|
|
Date of Report (Date of earliest event reported):
June 21, 2022
|
Mednax, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
Florida
|
001-12111
|
26-3667538
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
|
|
1301 Concord Terrace
|
|
|
Sunrise,
Florida
|
|
33323
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
|
Registrant’s Telephone Number, Including Area Code:
954
384-0175
|
(Former Name or Former Address, if Changed Since Last
Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, par value $.01 per share
|
|
MD
|
|
The New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01 Regulation FD Disclosure.
On June 21, 2022, Mednax, Inc., a Florida corporation (the
“Company”), issued a press release announcing that the Company will
change its corporate name to “Pediatrix Medical Group, Inc.,”
effective after the close of the market on July 1, 2022. The
Company’s common stock, par value $0.01 per share (“Common Stock”),
will continue to trade on the New York Stock Exchange under the
current ticker symbol “MD.” No action is necessary on the part of
Company shareholders in connection with the name change; existing
certificates that represent shares of Mednax, Inc. Common Stock
will continue to represent shares of Pediatrix Medical Group, Inc.
Common Stock after the name change.
A copy of the press release is furnished as Exhibit 99.1 hereto and
incorporated by reference herein. The information contained in this
Item 7.01, including Exhibit 99.1, shall not be deemed “filed” with
the Securities and Exchange Commission nor incorporated by
reference in any registration statement or other document filed by
the Company under the Securities Act of 1933, except as shall be
expressly set forth by specific reference in such
filing.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit Index
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
Mednax, Inc.
|
|
|
|
|
|
|
Date:
|
June 21, 2022
|
By:
|
/s/ C. Marc Richards
|
|
|
|
|
C. Marc Richards
Chief Financial Officer
|
Pediatrix Medical (NYSE:MD)
Historical Stock Chart
From Dec 2022 to Jan 2023
Pediatrix Medical (NYSE:MD)
Historical Stock Chart
From Jan 2022 to Jan 2023
